東華大學圖書館 |

Development of Molecular Glue Degraders as Probes and Therapeutic Agents.

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Development of Molecular Glue Degraders as Probes and Therapeutic Agents./
作者:	Miyamoto, David.
面頁冊數:	1 online resource (497 pages)
附註:	Source: Dissertations Abstracts International, Volume: 84-12, Section: B.
Contained By:	Dissertations Abstracts International84-12B.
標題:	Cellular biology. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=30491061click for full text (PQDT)
ISBN:	9798379612566

Development of Molecular Glue Degraders as Probes and Therapeutic Agents.
Miyamoto, David.

Development of Molecular Glue Degraders as Probes and Therapeutic Agents. - 1 online resource (497 pages)

Source: Dissertations Abstracts International, Volume: 84-12, Section: B.

Thesis (Ph.D.)--Harvard University, 2023.

Includes bibliographical references

Immunomodulatory drugs (IMiDs) function as molecular glues between the E3 ligase substrate receptor cereblon (CRBN) and protein substrates. The formation of this ternary complex results in the substrates' ubiquitination and proteasomal degradation. The field of targeted protein degradation has extensively utilized this unique mechanism of action to degrade various protein substrates to study biological processes and for therapeutic applications. Here, using a structure-guided approach, I develop novel small molecules based on the IMiDs to degrade various proteins implicated in disease.In chapter 1, I discuss the history of the IMiDs and describe the structural basis for their substrate scope. I review the major proteins that are degraded by the IMiDs and how they were discovered and the structural basis for the IMiD's engagement of neosubstrates. I also discuss the ongoing efforts to degrade these substrates and their therapeutic applications in various diseases.In chapter 2, I report the medicinal chemistry efforts to develop a small molecule that degrades the transcription factor Ikaros zinc finger protein 2 (IKZF2) and casein kinase 1 alpha (CK1α) both of which are targets in acute myeloid leukemia (AML). I discuss the structural basis for changing the selectivity of the IMiD lenalidomide to degrade IKZF2 and describe the small library of molecules based on its scaffold that I synthesized. I then detail the extensive medicinal chemistry efforts to optimize IKZF2 degradation to afford lead compound 35. I show that 35 additionally degrades CK1α and describe efforts to optimize 35 for solubility and metabolic stability. These efforts resulted in degrader 77 which potently degrades IKZF2 and CK1α and shows cell killing activity in AML and ovarian cancer cell lines.In chapter 3 I report the use of 35 and 77 in the context of AML. I report that 35 and 77 degrade IKZF2 and CK1α across multiple AML cell lines and induce apoptosis and differentiation. I then describe the validation of these molecules as molecular glues and show using a high throughput screen that they are selective against certain cancer types including AML. I then report the phenotypic effects of IKZF2 and CK1α degradation separately and find that IKZF2 degradation leads to differentiation while CK1α degradation leads to apoptosis, cell cycle arrest, and differentiation. Finally, I report the use of 35 and 77 in vivo in various AML models and show that 77 treatment delays AML disease progression and nearly double the lifespan of mice with AML.Finally, in chapter 4 I describe efforts to develop chemical tools to study small molecule-protein interactions. While not directly related to protein degradation with molecular glues, this chapter highlights the ability of chemical tools to reveal structural insights into small molecule-protein interactions such as those discussed in previous chapters. I describe the development and optimization of a cleavable biotin picolyl azide probe that can be used to identify small molecule binding sites. Using this probe, I report a novel binding site of celecoxib on prostaglandin E synthase.

Electronic reproduction.
Ann Arbor, Mich. :
ProQuest,
2023

Mode of access: World Wide Web

ISBN: 9798379612566Subjects--Topical Terms:

3172791
Cellular biology.
Subjects--Index Terms:

Immunomodulatory drugsIndex Terms--Genre/Form:

542853
Electronic books.

Development of Molecular Glue Degraders as Probes and Therapeutic Agents.
LDR:04628nmm a2200421K 4500 001 2363037
005 20231109104740.5
006 m o d
007 cr mn ---uuuuu
008 241011s2023 xx obm 000 0 eng d
020 $a 9798379612566
035 $a (MiAaPQ)AAI30491061
035 $a AAI30491061
040 $a MiAaPQ $b eng $c MiAaPQ $d NTU
100 1 $a Miyamoto, David. $3 3703783
245 1 0 $a Development of Molecular Glue Degraders as Probes and Therapeutic Agents.
264 0 $c 2023
300 $a 1 online resource (497 pages)
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
500 $a Source: Dissertations Abstracts International, Volume: 84-12, Section: B.
500 $a Includes supplementary digital materials.
500 $a Advisor: Woo, Christina.
502 $a Thesis (Ph.D.)--Harvard University, 2023.
504 $a Includes bibliographical references
520 $a Immunomodulatory drugs (IMiDs) function as molecular glues between the E3 ligase substrate receptor cereblon (CRBN) and protein substrates. The formation of this ternary complex results in the substrates' ubiquitination and proteasomal degradation. The field of targeted protein degradation has extensively utilized this unique mechanism of action to degrade various protein substrates to study biological processes and for therapeutic applications. Here, using a structure-guided approach, I develop novel small molecules based on the IMiDs to degrade various proteins implicated in disease.In chapter 1, I discuss the history of the IMiDs and describe the structural basis for their substrate scope. I review the major proteins that are degraded by the IMiDs and how they were discovered and the structural basis for the IMiD's engagement of neosubstrates. I also discuss the ongoing efforts to degrade these substrates and their therapeutic applications in various diseases.In chapter 2, I report the medicinal chemistry efforts to develop a small molecule that degrades the transcription factor Ikaros zinc finger protein 2 (IKZF2) and casein kinase 1 alpha (CK1α) both of which are targets in acute myeloid leukemia (AML). I discuss the structural basis for changing the selectivity of the IMiD lenalidomide to degrade IKZF2 and describe the small library of molecules based on its scaffold that I synthesized. I then detail the extensive medicinal chemistry efforts to optimize IKZF2 degradation to afford lead compound 35. I show that 35 additionally degrades CK1α and describe efforts to optimize 35 for solubility and metabolic stability. These efforts resulted in degrader 77 which potently degrades IKZF2 and CK1α and shows cell killing activity in AML and ovarian cancer cell lines.In chapter 3 I report the use of 35 and 77 in the context of AML. I report that 35 and 77 degrade IKZF2 and CK1α across multiple AML cell lines and induce apoptosis and differentiation. I then describe the validation of these molecules as molecular glues and show using a high throughput screen that they are selective against certain cancer types including AML. I then report the phenotypic effects of IKZF2 and CK1α degradation separately and find that IKZF2 degradation leads to differentiation while CK1α degradation leads to apoptosis, cell cycle arrest, and differentiation. Finally, I report the use of 35 and 77 in vivo in various AML models and show that 77 treatment delays AML disease progression and nearly double the lifespan of mice with AML.Finally, in chapter 4 I describe efforts to develop chemical tools to study small molecule-protein interactions. While not directly related to protein degradation with molecular glues, this chapter highlights the ability of chemical tools to reveal structural insights into small molecule-protein interactions such as those discussed in previous chapters. I describe the development and optimization of a cleavable biotin picolyl azide probe that can be used to identify small molecule binding sites. Using this probe, I report a novel binding site of celecoxib on prostaglandin E synthase.
533 $a Electronic reproduction. $b Ann Arbor, Mich. : $c ProQuest, $d 2023
538 $a Mode of access: World Wide Web
650 4 $a Cellular biology. $3 3172791
650 4 $a Pharmaceutical sciences. $3 3173021
650 4 $a Immunology. $3 611031
653 $a Immunomodulatory drugs
653 $a Proteasomal degradation
653 $a Metabolic stability
653 $a Molecular glue degraders
653 $a Therapeutic agents
653 $a Chemical tools
655 7 $a Electronic books. $2 lcsh $3 542853
690 $a 0379
690 $a 0982
690 $a 0572
710 2 $a ProQuest Information and Learning Co. $3 783688
710 2 $a Harvard University. $b Chemistry and Chemical Biology. $3 2094763
773 0 $t Dissertations Abstracts International $g 84-12B.
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=30491061 $z click for full text (PQDT)